Drug Trial Radar · NCT07606833
The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
Last checked: Nov 19, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
556
Planned (sponsor's estimate)
Start
Jun 10, 2026
Primary completion
Feb 19, 2027
Study completion Mar 18, 2027
Sponsor
- Lead sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple therapy for eradication of Helicobacter pylori in China.
Conditions
- HELICOBACTER PYLORI INFECTIONS
Interventions
Anaprazole Sodium enteric-coated tabletDrug
Anaprazole sodium enteric-coated tablets 20mg + Esomeprazole magnesium enteric-coated tablets placebo 1 tablet +Bismuth potassium citrate capsules 240mg + Amoxicillin capsules 1000mg + Clarithromycin tablets 500mg,BID,oral,twice daily for 14 days
Esomeprazole magnesium enteric-coated tabletsDrug
Anaprazole sodium enteric-coated tablets placebo 1 tablet + Esomeprazole magnesium enteric-coated tablets20mg +Bismuth potassium citrate capsules 240mg + Amoxicillin capsules 1000mg + Clarithromycin tablets 500mg,BID,oral,twice daily for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of all participants with successful Helicobacter Pylori (Hp) eradicationTime frame: Day 28+7 days following the completion of treatment(duration of treatment was 2 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shenzhen Hospital of Southern Medical University
Shenzhen, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.